Health and medical contexts have emerged as an important area of inquiry for researchers at the intersection of user experience and technical communication. In addressing this intersection, this article advocates and extends patient experience design or PXD ( Melonçon, 2017 ) as an important framework for user experience research within health and medicine. Specifically, this article presents several PXD insights from a task-based usability study that examined an online intervention program for people with voice problems. We respond to Melonçon's call ( 2017 ) to build PXD as a framework for user experience and technical communication research by describing ways traditional usability methods can provide PXD insights and asking the following question: What insights can emerge from combining traditional usability methods and PXD research? In addressing this question, we outline two primary methodological and practical considerations we found central to conducting PXD research: (1) engaging patients as participants, and (2) leveraging multidisciplinary collaboration.

Recent research in rhetoric of health and medicine (RHM) has worked to evaluate the effectiveness of patient inclusion initiatives in health policy decision-making. Extending this line of research, this article evaluates the extent to which the U.S. Food and Drug Administration’s (FDA) patient and consumer representative programs meaningfully engage patient experiences. In so doing, this study provides directed and summative content analyses of pharmaceuticals policy deliberation at 163 FDA drug advisory committee meetings. The results indicate that the current implementation of the patient and consumer representative programs do not adequately ensure that patient experiences are being included as a part of advisory committee deliberation or subsequent pharmaceuticals policy. Additionally, the results presented support the growing concern that attempts to include patient perspectives in health policy may actually further marginalize patient populations.

This article examines prescription drug labels (PDLs) via an actor-network theory analysis to demonstrate current challenges with technical communication (TC) scholars’ appropriation of actor-network theory. The authors demonstrate that the complexity of the PDL network requires a more nuanced deployment of actor-network theory notions of durability and synchronicity. Specifically, the authors suggest that diachronic approaches to networks enable a more comprehensive understanding in ways that synchronic approaches cannot.